# Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

> **NCT00721734** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 50 (actual)

## Conditions studied

- Multiple Myeloma
- Renal Insufficiency

## Interventions

- **DRUG:** Carfilzomib

## Key facts

- **NCT ID:** NCT00721734
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2017-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00721734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00721734, "Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00721734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*